Mirum Pharmaceuticals, Inc. (MIRM) Stock: Price, Forecast & Analyst Target
Mirum Pharmaceuticals, Inc. (MIRM) — MoonshotScore 14/100 (Weak band), calculated Nov 18, 2026. Price $96.13 (+0.65%), as of the Nov 20, 2026 trading session; market cap $6.28B.
Educational signal · not a buy or sell recommendation · How to read this
Mirum Pharmaceuticals, Inc. · MIRM · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Mirum Pharmaceuticals develops therapies for rare, inherited liver diseases where few alternatives exist. The company has one commercial drug generating revenue and a second in development, but both remain in early regulatory and clinical stages. Success or failure depends almost entirely on FDA decisions and clinical trial outcomes, not market share or operational efficiency.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Mirum Pharmaceuticals (MIRM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — weak quality underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Fading; Momentum: Rising.
- EPS beat 0 of the last 4 reports
- Altman Z -0.51 · Piotroski F 3
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 15 | Weak | |
| 15 | Weak | |
| 15 | Weak | |
| 14 | Weak | |
| 14 | Weak | |
| 14 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $96.13 | |
| Change on the day | +0.65% | |
| 52-week range | $63.23–$130.00 | |
| Market capitalisation | $6.28B | — |
| Price / earnings (trailing) | -181.90 | |
| Shares traded on the day | 1.06M | |
| Beta (volatility vs the S&P 500) | 0.74 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Mirum Pharmaceuticals (MIRM): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Mirum Pharmaceuticals (MIRM), and what does it report?
Short answer · as of
Mirum is a biopharmaceutical firm with a single product on the market—LIVMARLI, an oral treatment for progressive familial intrahepatic cholestasis and related cholestatic liver diseases.
Research dated 2026-09-13.
The company sells this drug while simultaneously conducting trials for bile acid modulators in pregnancy-related and autoimmune liver conditions. Revenue comes from LIVMARLI sales; costs are almost entirely research and development staff trying to bring the second drug to the market.
The reported numbers reflect a company at an inflection point. Quarterly revenue has grown steadily since the drug launched, but operating expenses dwarf sales because the second program demands a full research workforce. The income statement shows deepening losses on a generally expanding revenue base, which is typical for early commercialization of a specialty rare-disease therapy.
What do the latest results show for Mirum Pharmaceuticals (MIRM)?
Research dated 2026-09-13.
The most recent quarter showed revenue growth, with gross margins above realistic levels for a specialty pharma despite fixed manufacturing costs. Operating losses widened, however, as research intensity increased in preparation for regulatory submissions. Cash flow deteriorated sharply in the same period, driven both by higher operating burn and by the timing of cash receipts and payables—a temporary pattern, but one that compounds when runway is already finite.
Analyst revisions have been volatile, suggesting uncertainty about trial timelines and commercial ramp. The most recent earnings report surprised to the downside on per-share loss, though revenue itself met guidance, indicating that cost controls slipped rather than sales momentum failed.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $133M | $3M | $0.05 (diluted) |
| Q4 FY2025 | $149M | -$6M | -$0.11 (diluted) |
| Q1 FY2026 | $160M | -$790M | -$13.43 (diluted) |
| Q2 FY2026 | $176M | -$67M | -$1.06 (diluted) |
What are the financial strengths and risks for Mirum Pharmaceuticals (MIRM)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Mirum holds enough cash and short-term investments to fund operations for roughly another year and a half, a runway that extends into the period when regulatory decisions on the second drug become likely. The balance sheet shows strong liquidity ratios, meaning the company can cover near-term obligations easily. Debt is modest relative to cash, and the company carries no catastrophic lease or pension obligations.
The central risk is not balance-sheet fragility but clinical and regulatory outcomes. If trials succeed and the FDA approves, the company moves to profitability quickly under analyst models. If trials stall or regulators demand more data, the company exhausts cash before generating enough revenue to sustain itself. Insiders have not purchased shares in the past half-year despite what would normally be attractive valuations after a recent price decline, a signal that insiders expect uncertainty to persist.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -0.51 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Mirum Pharmaceuticals (MIRM)?
Short answer · as of
Current published price targets run low $130.00 · high $202.00 · consensus $154.82 · median $146.00 against a quoted price of $96.13 (as of Nov 20, 2026).
Research dated 2026-09-13.
The next material event is the FDA's response to pending submissions for LIVMARLI in additional indications and for Volixibat. Approval dates should be disclosed within the coming quarters. Commercial scaling, if approved, will move from aspirational to observable in pricing discussions and insurance negotiation announcements.
Analyst estimates project profitability within several years, conditional on both drugs reaching the market and capturing expected pricing. Each trial readout, regulatory decision, and quarterly revenue update will either validate or undermine these assumptions. The company also faces the question of whether cash on hand suffices to reach break-even, or whether a financing round becomes necessary before then.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Mirum Pharmaceuticals compare with its peers?
Short answer
Mirum Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Rare-disease biotech operates on a fundamentally different model than broad-market pharmaceutical companies. Success is not about market share or competitive pricing; it is about regulatory approval and patient identification in a small population. Mirum has no generic or biosimilar competitors and faces no price pressure from volume alone—the limiting constraint is FDA acceptance and insurance coverage.
Compared to other rare-disease companies at similar clinical and commercial stages, Mirum's cash runway and burn rate are within normal bounds. Unlike early-stage pure biotech firms without approved drugs, Mirum has proof of commercial demand through LIVMARLI sales. Unlike large pharmaceutical corporations, it carries no legacy costs, no portfolio diversification, and no defensive marketing burden. The difference is not quality but structure: Mirum succeeds or fails on a single therapeutic area and a handful of clinical programs.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.89 Nov 20, 2026 | $7.38B | 98 5-pillar Nov 18, 2026 | |
| $308.89 Nov 20, 2026 | $9.15B | 96 5-pillar Nov 18, 2026 | |
| $91.35 Nov 20, 2026 | $10.4B | 95 5-pillar Nov 18, 2026 | |
| $63.62 Nov 20, 2026 | $6.96B | 91 5-pillar Nov 18, 2026 | |
| $63.34 Nov 20, 2026 | $9.57B | 90 5-pillar Nov 18, 2026 | |
| $121.40 Nov 20, 2026 | $7.92B | 88 5-pillar Nov 18, 2026 | |
| $39.91 Nov 20, 2026 | $4.37B | 84 5-pillar Nov 18, 2026 | |
| $17.58 Nov 20, 2026 | $5.04B | 83 5-pillar Nov 18, 2026 | |
| $286.85 Nov 20, 2026 | $5.74B | 71 5-pillar Nov 18, 2026 | |
| $95.81 Nov 20, 2026 | $6.50B | 67 5-pillar Nov 18, 2026 | |
| $13.61 Nov 20, 2026 | $4.78B | 67 5-pillar Nov 18, 2026 | |
| $119.52 Nov 20, 2026 | $5.04B | 66 5-pillar Nov 18, 2026 | |
| Mirum Pharmaceuticals (MIRM) — this page | $96.13 | $6.28B | 14 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $130.00 – $202.00
- Consensus target
- $154.82
- Median target
- $146.00
Consensus record · Captured .
Measured against a quoted price of $96.13 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 11, 2026
- Transactions
- 59
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 23
- Other transactions
- 36
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MIRM in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MIRM in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Mirum Pharmaceuticals (MIRM)?
Mirum Pharmaceuticals Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is LIVMARLI and when did it launch?
LIVMARLI is an oral therapy for inherited cholestatic liver disease, the only approved drug in its class for progressive familial intrahepatic cholestasis. The company has been commercializing it and expanding clinical trials to additional disease conditions where the same mechanism may apply.
How much longer can the company operate without profitability?
Mirum's current cash and investments support operations for roughly another year and a half if burn rates remain stable. This window aligns with expected regulatory and trial readout timelines, but does not provide margin for delays. If trials slow or FDA decisions take longer than anticipated, the company may require additional financing.
Why are insiders selling shares?
Insiders have executed restricted stock vesting and have sold shares in the open market, a pattern consistent with tax-withholding and diversification rather than distress sales. However, the absence of any insider purchases in the past half-year suggests no conviction that the current valuation offers sufficient margin of safety to warrant personal investment.
What is the single biggest uncertainty for this stock?
FDA approval decisions and clinical trial outcomes for both LIVMARLI extensions and Volixibat will determine whether Mirum reaches sustainable profitability or exhausts cash and must dilute shareholders. Investors have no way to predict or control these outcomes; they can only wait for reports and trial readouts. The company's success or failure is binary in a way that operational improvements cannot remedy.
What is the MIRM stock price today?
The last price recorded for Mirum Pharmaceuticals, Inc. (MIRM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MIRM price target?
The analyst consensus price target for Mirum Pharmaceuticals, Inc. (MIRM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 22 figures on this page — 19 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold MIRM
Funds in our ETF coverage that list MIRM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| State Street SPDR S&P Biotech ETF (XBI) | 1.41% | |
| Federated Hermes MDT Small Cap Core ETF (FSCC) | 1.31% |